Home / Business and Economy / Eris Lifesciences Sees Profit Skyrocket 3x in Q4
Eris Lifesciences Sees Profit Skyrocket 3x in Q4
20 May
Summary
- Consolidated net profit tripled to ₹281.6 crore in Q4 FY26.
- Full-year profit surged 76% to ₹619.5 crore for FY26.
- Insulin franchise outpaced market growth fivefold in FY26.
Eris Lifesciences announced a substantial three-fold increase in its consolidated net profit for the fourth quarter of FY26, reaching ₹281.6 crore. This surge was accompanied by a 7.3% rise in revenue from operations, totaling ₹756.5 crore.
For the full fiscal year 2026, Eris Lifesciences experienced a significant profit jump of 76%, accumulating ₹619.5 crore. The company's revenue from operations for the entire year grew by 8% to ₹3,129.4 crore.
Amit Bakshi, chairman and managing director, highlighted an 11% revenue growth in the domestic formulations business for FY26, with an 11% Ebitda growth and an industry-leading Ebitda margin of 37%.
The company's insulin franchise significantly outpaced market growth, expanding its market share from 12% to 16% during FY26. The recent launch of the GLP brand Sundae also made a strong debut, capturing the top spot in injectables by volume in its first month.
